View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Oct. 30, 2015
Document Information [Line Items]
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	OPGN
Entity Common Stock, Shares Outstanding		12,539,704
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 11,187,129	$ 749,517
Accounts receivable, net	553,938	503,983
Inventory, net	1,155,488	369,742
Prepaid expenses and other current assets	538,312	90,233
Total current assets	13,434,867	1,713,475
Property and equipment, net	1,021,971	587,956
Deferred IPO issuance costs	0	296,041
Intangible assets, net	1,955,769	0
Goodwill	291,747	0
Other noncurrent assets	293,135	57,459
Total assets	16,997,489	2,654,931
Current liabilities
Accounts payable	1,274,657	1,160,081
Accrued compensation and benefits	840,637	423,099
Accrued liabilities	1,232,328	993,657
Deferred revenue	158,860	339,171
Short-term notes payable	1,250	1,505,000
Current maturities of long-term capital lease obligations	227,049	100,499
Short-term convertible notes, net of discounts	0	1,500,000
Total current liabilities	3,734,781	6,021,507
Note payable	1,000,000	0
Long-term capital lease obligations and other noncurrent liabilities	317,854	134,149
Total liabilities	5,052,635	6,155,656
Commitments and contingencies (Note 10)
Redeemable convertible preferred stock
Redeemable convertible preferred stock	0	4,564,899
Stockholders' equity (deficit)
Common stock, $.01 par value; 200,000,000 shares authorized; 12,539,704 and 493,178 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	125,397	4,932
Additional paid-in capital	121,216,140	88,701,737
Accumulated other comprehensive loss	(49)	0
Accumulated deficit	(109,396,634)	(96,772,293)
Total stockholders' equity (deficit)	11,944,854	(8,065,624)
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	16,997,489	2,654,931
Series A Convertible Redeemable Preferred Stock
Redeemable convertible preferred stock
Redeemable convertible preferred stock	$ 0	$ 4,564,899

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	12,539,704	493,178
Common stock, shares outstanding	12,539,704	493,178
Series A Convertible Redeemable Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	0	3,999,864
Preferred stock, shares outstanding	0	3,999,864
Preferred stock, liquidation preference	$ 0	$ 7,999,728

Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue
Product sales	$ 929,241	$ 268,854	$ 1,432,592	$ 841,567
Laboratory services	23,765	88,190	87,201	379,339
Collaboration revenue	27,780	477,780	308,340	1,783,340
Total revenue	980,786	834,824	1,828,133	3,004,246
Cost of products sold (excluding depreciation and amortization)	562,694	101,425	712,016	276,831
Cost of services (excluding depreciation and amortization)	46,634	129,120	191,738	336,616
Total costs of sales (excluding depreciation and amortization)	609,328	230,545	903,754	613,447
Gross profit	371,458	604,279	924,379	2,390,799
Operating expenses
Research and development	1,724,127	1,029,650	3,741,247	3,075,420
General and administrative	1,610,828	555,444	3,687,313	1,590,085
Sales and marketing	979,681	459,064	2,815,976	1,486,801
Depreciation and amortization	185,177	141,060	392,404	461,432
Transaction expenses	525,596	0	525,596	0
Total operating expenses	5,025,409	2,185,218	11,162,536	6,613,738
Operating loss	(4,653,951)	(1,580,939)	(10,238,157)	(4,222,939)
Other income (expense)
Interest income	2,513	37	9,675	120
Interest expense	(17,482)	(32,331)	(1,746,853)	(47,468)
Change in fair value of derivative financial instruments and other	0	4,400	(647,342)	4,400
Total other income (expense)	(14,969)	(27,894)	(2,384,520)	(42,948)
Loss before income taxes	(4,668,920)	(1,608,833)	(12,622,677)	(4,265,887)
Provision for income taxes	1,662	0	1,662	0
Net loss	(4,670,582)	(1,608,833)	(12,624,339)	(4,265,887)
Preferred stock dividends	0	(175,246)	(244,508)	(458,799)
Net loss available to common stockholders	$ (4,670,582)	$ (1,784,079)	$ (12,868,847)	$ (4,724,686)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.38)	$ (4.92)	$ (2.00)	$ (13.03)
Weighted average shares outstanding - basic and diluted (in shares)	12,261,238	362,537	6,444,373	362,537
Net loss	$ (4,670,582)	$ (1,608,833)	$ (12,624,339)	$ (4,265,887)
Other comprehensive loss - foreign currency translation	(49)	0	(49)	0
Comprehensive loss	$ (4,670,631)	$ (1,608,833)	$ (12,624,388)	$ (4,265,887)

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (12,624,339)	$ (4,265,887)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	392,404	461,432
Deferred tax provision	1,662	0
Noncash interest expense	1,598,312	20,883
Share-based compensation	1,172,231	80,457
Inventory obsolescence	0	(44,595)
Change in fair value of derivative financial instruments and other	647,342	(4,400)
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	507,066	62,251
Inventory	288,126	(159,174)
All other assets	(306,386)	78,311
Accounts payable	(814,855)	29,853
Accrued compensation and other liabilities	(1,752,790)	(42,778)
Deferred revenue	(180,311)	(121,551)
Net cash used in operating activities	(11,071,538)	(3,905,198)
Cash flows from investing activities
Cash acquired in business combination	1,367,211	0
Purchases of property and equipment	(89,234)	(39,537)
Net cash provided by (used in) investing activities	1,277,977	(39,537)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	4,958,335	0
Proceeds from issuance of preferred stock, net of issuance costs	0	1,937,902
Proceeds from issuance of convertible notes and warrants, net of issuance costs	1,388,815	1,472,386
Proceeds from issuance of promissory notes, net of issuance costs	1,741,667	0
Proceeds from exercise of stock options and warrants	214	0
Proceeds from initial public offering, net of issuance costs paid in 2015	12,408,285	0
Payments on debt	(153,750)	(3,750)
Payments on capital lease obligations	(112,200)	(80,575)
Net cash provided by financing activities	20,231,366	3,325,963
Effects of exchange rates on cash	(193)	0
Net (decrease) increase in cash and cash equivalents	10,437,612	(618,772)
Cash and cash equivalents at beginning of period	749,517	1,400,345
Cash and cash equivalents at end of period	11,187,129	781,573
Supplemental disclosure of cash flow information
Cash paid during the period for interest	201,233	26,088
Supplemental disclosure of noncash investing and financing activities:
Acquisition of equipment purchased through capital leases	429,320	0
Common stock issued in business combination	2,584,090	0
Debt Conversion, Converted Instrument, Amount	300,000	0
IPO [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	2,100,000	0
Series A Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	$ 3,000,000	$ 0

Organization

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1 - Organization

OpGen, Inc. (“OpGen”) was incorporated in Delaware in 2001. On July 14, 2015, OpGen completed the strategic acquisition (the “Merger”) of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, “AdvanDx”) (see Note 4). Pursuant to the terms of a merger agreement, Velox Acquisition Corp. (OpGen’s wholly owned subsidiary formed for the express purpose of enacting the Merger) merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as OpGen’s wholly owned subsidiary (see Note 4). OpGen, AdvanDx, Inc. and AdvanDx A/S are collectively referred to hereinafter as the “Company.” The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark.

OpGen is an early-stage company using rapid molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections, or MDROs. OpGen’s lead products are its QuickFISH® and PNAFISH products, which are advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, the Acuitas® MDRO Gene Test, a CLIA lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection and the Acuitas Lighthouse to aid in the interpretation of MDRO diagnostic test results. The company develops, markets and sells its products principally for use in hospitals and clinical laboratories in the United States and internationally.

The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.

Liquidity and management's plans

9 Months Ended

Sep. 30, 2015

Liquidation Basis Of Accounting Abstract [Abstract]

Liquidity and management’s plans

Note 2 – Liquidity and management’s plans

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements. The Company raised significant funds in 2015, including:

$0.8 million in short-term notes (in the first quarter of 2015, $0.3 million of demand notes held by an entity controlled by our chief executive officer were settled as partial payment for a 2015 convertible note, and in the second quarter of 2015, $0.2 million of notes from a related party were repaid in cash),

$1.5 million through the issuance of convertible notes,

$12.1 million in net proceeds from its initial public offering, or IPO, as discussed further below, and

$6.0 million in net proceeds from the issuances of common stock and promissory note to Merck Global Health Innovations Fund, LLC (“Merck GHI”).

On May 8, 2015, OpGen completed its IPO pursuant to which it offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds were $12.1 million. On the IPO closing date, the underwriters exercised their over-allotment option to acquire an additional 422,500 stock purchase warrants. In connection with the IPO, all of OpGen’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

In July 2015, the Company raised $6.0 million by issuing 1,136,364 shares of common stock (with a value of $5.0 million at $4.40 per share) and a $1.0 million promissory note to Merck GHI (see Note 5).

The Company’s current operating assumptions, which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations through at least the end of the first quarter of 2016. In the event the Company is unable to successfully raise additional capital in 2016, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Summary of significant accounting policies

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 3 - Summary of significant accounting policies

Basis of presentation and consolidation

The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles, or GAAP, for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 previously filed with the SEC. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1/A and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2015 and the results of operations and cash flows for the three and nine months ended September 30, 2015 and 2014. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited interim condensed consolidated financial statements include the accounts of the OpGen and its wholly owned and controlled subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment. Certain prior period information has been reclassified to conform to the current period presentation.

Foreign Currency

AdvanDx A/S is located in Copenhagen, Denmark and uses the Danish Krone as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at September 30, 2015.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instrument s. The carrying value of the Company’s debt is reflective of fair value based on instruments with similar terms available to the Company.

Cash and cash equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

Accounts receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 45 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $79,697 as of September 30, 2015 and December 31, 2014, respectively.

At September 30, 2015, the Company had accounts receivable from two customers which individually represented 12% and 11% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represented 79%, and 15% of total accounts receivable.

Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	September 30,		December 31,
	2015		2014

Raw materials and supplies	$	697,414	$	40,749
Work-in process		222,031		135,625
Finished goods		236,043		193,368
Total	$	1,155,488	$	369,742

Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNAFISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $778,944 and $867,816 at September 30, 2015 and December 31, 2014, respectively.

Product warranty

A warranty reserve is established upon the sale of any Argus System or Whole Genome Mapping product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty. The reserve for warranties was $2,750 as of September 30, 2015 and December 31, 2014, respectively.

Impairment of property and equipment

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.

Definite-lived intangible assets

Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of 10, 7 and 7 years, respectively. Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of the Merger, the Company recognized goodwill of approximately $292,000.

The Company will conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value.

Redeemable convertible preferred stock

All shares of Series A redeemable convertible preferred stock, or Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 7).

Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had 3,999,864 shares of Series A Preferred Stock, outstanding. The Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.

When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.

Revenue from sales of AdvanDx diagnostic products

Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Share-based compensation

Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized. The Company’s tax provision for the three and nine months ended September 30, 2015 resulted from the deductibility of goodwill for tax purposes.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss, or NOL, carryforwards of $76,267,809 at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 5.7 million and 6.1 million for the nine and three months ended September 30, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

Business Combination

9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Business Combination

Note 4 – Business Combination

On July 14, 2015, the Company completed the Merger by acquiring 100% of the capital stock of AdvanDx in the Merger in a taxable transaction. AdvanDx researches, develops and markets advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to exploit AdvanDx’s diagnostic capabilities with respect to MDROs and leverage AdvanDx’s relationships with hospitals and clinical laboratories to accelerate the sales of OpGen’s products and services.

Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), Velox Acquisition Corp. merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the merger consideration consisted of an aggregate 681,818 shares of the Company's common stock with a value of $2.6 million (the “Merger Consideration”), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx, Inc. Restated Certificate of Incorporation, as amended.

The Company accounted for its acquisition of AdvanDx by recording all tangible and intangible assets acquired and liabilities assumed at their estimated fair values on the acquisition date, with the remaining unallocated purchase price recorded as goodwill. The fair value assigned to identifiable intangible assets acquired was determined using an income approach for trade names and customer relationships, and a cost approach for technology. The fair values are based on the Company’s estimates and may be adjusted from time to time, but no later than July 13, 2016, as better information becomes available. The Company received stepped-up bases in the acquired assets and liabilities and therefore did not recognize any deferred income tax assets and liabilities. The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued	$	2,584,090

Fair value of tangible assets acquired:
Cash		1,367,211
Receivables		557,112
Inventory		1,073,855
Property and equipment		250,636
Other assets		359,587
Fair value of identifiable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		291,747

Fair value of liabilities assumed		3,329,058
	$	2,584,090

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $0.3 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is tax deductible in all relevant taxing jurisdictions. The Company expensed acquisition-related costs of approximately $0.5 million related to the Merger in 2015. AdvanDx recognized approximately $0.8 million of revenue and $0.8 million of net losses from the acquisition date to September 30, 2015, which results are included in the Company’s 2015 interim condensed consolidated financial statements.

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

Unaudited pro forma results	Nine months ended				Three months ended
	September 30,		September 30,		September 30,		September 30,
	2015		2014		2015		2014

Revenues	$	3,902,337	$	6,631,510	$	1,126,530	$	1,955,894
Net loss	$	(15,623,109)	$	(11,784,997)	$	(4,650,817)	$	(4,517,541)
Net loss per share	$	(2.29)	$	(11.72)	$	(0.38)	$	(4.49)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Merck GHI Financing

9 Months Ended

Sep. 30, 2015

Common Stock and Note Purchase Agreement [Abstract]

Common Stock and Note Purchase Agreement [Text Block]

Note 5 – Merck GHI Financing

On July 14, 2015, as a condition to the Merger, the Company entered into a Common Stock and Note Purchase Agreement (the “Purchase Agreement”) with Merck GHI, pursuant to which Merck GHI purchased 1,136,364 shares of common stock of the Company at $4.40 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a 8% Senior Secured Promissory Note (the “Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company's obligations under the Note are secured by a lien on all of the Company's assets.

The Company incurred issuance costs of approximately $50,000 related to the financing, of which approximately $8,000 was deferred as debt issuance costs and are being amortized as interest expense over the life of the Note, and $42,000 was charged to additional paid-in capital.

Fair value measurements

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair value measurements

Note 6 - Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level 1 - defined as observable inputs such as quoted prices in active markets;

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:

	Fair value at
	September 30,
	2015		Level 1		Level 2		Level 3
Cash and cash equivalents	$	11,187,129	$	11,187,129	$	-	$	-

	Fair value at
	December 31,
	2014		Level 1		Level 2		Level 3
Cash and cash equivalents	$	749,517	$	748,048	$	1,469	$	-

The Company’s Level 1 securities primarily consist of cash and cash equivalents, including money market funds and U.S. Treasury Notes; the Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.

Prior to its IPO, certain stock purchase warrants contained cash settlement features and, accordingly, the Company considered them to be derivative financial instruments and accounted for them at fair value using level 3 inputs. As a result of the Company’s IPO and elimination of the cash settlement features pursuant to their terms, those stock purchase warrants were reclassified to equity. For periods prior to the IPO, the Company determined the fair value of these derivative liabilities using a hybrid valuation method that consisted of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treated all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock ) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:

	Balance at								Balance at
	December		Established		Change in		Reclassified		September
Description	31, 2014		in 2015		Fair Value		to Equity		30, 2015

Derivative warrant liability	$	-	$	72,333	$	647,342	$	(719,675)	$	-

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and nine month periods ended September 30, 2015 and 2014.

See Note 4 for a discussion of the fair value of assets acquired and liabilities assumed in the Merger.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Series A redeemable convertible preferred stock

9 Months Ended

Sep. 30, 2015

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Series A redeemable convertible preferred stock

Note 7 – Series A redeemable convertible preferred stock

All shares of Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)) were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to the Company’s IPO, the Series A Preferred Stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

The Company issued 1,999,864 shares of Series A Preferred Stock in December 2013 at $1.00 per share in exchange for $1,999,864 in convertible promissory notes. In February 2014, the Company sold 1,405,096 shares of Series A Preferred Stock for gross proceeds of $1,405,096. In April 2014, the Company sold an additional 594,904 shares of Series A Preferred Stock for gross proceeds of $594,904. At December 31, 2014, the Company had a total of 3,999,864 shares of Series A Preferred Stock outstanding, convertible into 3,999,864 shares of common stock.

The holders of the Series A Preferred Stock had the right to receive non-cumulative dividends, at a rate of 8% per annum, when and if declared by the Board of Directors. The Series A Preferred Stock had preference of payment over all other classes and series of capital stock of the Company with respect to dividends, payment on liquidation and payment on redemption. The liquidation and redemption preferences were at two times the Series A Preferred Stock purchase price. The Series A Preferred Stock holders were entitled to vote on all matters that come to stockholders on an as-converted basis with holders of the common stock. In addition, the Series A Preferred Stock had broad based anti-dilution rights.

The holders of Series A Preferred Stock had the right to convert such shares, at their option and at any time, into shares of common stock at the then-applicable conversion rate, as defined. The initial conversion rate was one common share for each preferred share, which could be adjusted for specified dilutive transactions. Beginning in December 2020, the Company may have been obligated to redeem shares of Series A Preferred Stock, if requested, by holders of at least 70% of the then-outstanding shares of preferred stock. The redemption, if requested, would have taken place in three equal annual installments. Series A Preferred Stock would have been redeemed at two times the original issue price per share plus all accrued and unpaid dividends. The redemptions were subject to certain equity adjustments for specified anti-dilution transactions, as defined.

Debt

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Debt

Note 8 - Debt

All the Company’s outstanding demand notes and convertible notes were exchanged for units in the Company’s IPO or otherwise were converted into Series A Preferred Stock and subsequently converted into shares of common stock in connection with the IPO. A short-term 8% promissory note for $150,000 issued in April 2015 was repaid in cash in June 2015. In July 2015, the Company issued a $1.0 million 8% senior secured promissory note to Merck GHI (see Note 5). As of September 30, 2015, the Company has a total of $1,001,250 debt outstanding.

Demand notes

In the fourth quarter of 2014 and first quarter of 2015, the Company raised a total of $2.3 million through the issuance of short-term demand notes. In the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note. All outstanding demand notes were tendered as payment for 350,000 units in the Company’s IPO (see Note 9). Prior to settlement, the demand notes bore interest at 8% per annum, had a first priority security interest in the assets of the Company, and a term of approximately four months.

2014 convertible debt

In July, August and September 2014, the Company raised $1.5 million through the issuance of convertible debt. All outstanding 2014 convertible debt was converted into Series A Preferred Stock and then into 1,500,000 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to its conversion, the debt was convertible, at the option of the holders or in certain cases at the Company’s option, into shares of Series A Preferred Stock or other potential equity securities, bore interest at 8% and was due in full on July 11, 2015.

2015 convertible debt

In February and March 2015, the Company raised $1.5 million in capital through the issuance of 8% secured convertible notes with detachable stock purchase warrants. All outstanding 2015 convertible debt was converted into Series A Preferred Stock and then into 1,875,000 shares of common stock in connection with the Company’s IPO (see Note 9). Prior to its conversion, the 2015 convertible notes were pre-payable by the Company without penalty at any time following the three-month anniversary of the closing of the IPO (provided that before the six-month anniversary of the closing of an IPO, the 2015 convertible notes could only be prepaid out of newly issued capital subsequent to the IPO), and were puttable by the holder to the Company in the event of a defined default. The 2015 convertible notes were each convertible, at the election of the holder, into (i) shares of Series A Preferred Stock, at a conversion rate of 1.25 shares of Series A Preferred Stock for each $1.00 converted if the conversion occurs prior to closing of an IPO, or (ii) shares of common stock at a conversion rate of one share of common stock for each $1.00 converted if the conversion occurs after the closing of an IPO.

The conversion option embedded in the convertible notes was determined to contain beneficial conversion features, resulting in the bifurcation of those features as an equity instrument (resulting in an additional debt discount) at issuance. After allocation of the gross proceeds to the detachable stock purchase warrants (discussed below) and beneficial conversion feature, the total debt discount recognized was equal to the face value of the 2015 convertible notes. Upon conversion in May 2015, the remaining unamortized beneficial conversion feature of approximately $1.5 million was charged to interest expense in the accompanying condensed consolidated statement of operations. Remaining unamortized deferred financing costs of $71,421 were also charged to interest expense upon conversion.

The 2015 convertible note holders also received detachable stock purchase warrants exercisable for 225,011 shares of common stock at 110% of the IPO price and exercisable only if the IPO occurred, and then exercisable beginning on the six-month anniversary of the closing of the IPO. Prior to the IPO, as a result of net settlement features, the stock purchase warrants were considered derivative liabilities, were initially recorded at fair value (resulting in a debt discount) and were marked-to-market at each balance sheet date through earnings. As a result of the elimination of the net settlement features in the IPO, the stock purchase warrants were marked to fair value of $0.7 million on May 8, 2015 and then reclassified to equity.

Stockholders' equity (deficit)

9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Stockholders' equity (deficit)

Note 9 - Stockholders’ equity (deficit)

On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes. After considering the demand notes, and underwriting discounts, commissions and offering expenses of $2.9 million (which were charged to additional paid in capital), the total net cash proceeds to the Company was $12.1 million. On the IPO closing date, the underwriters exercised a portion of their over-allotment option to acquire an additional 422,500 stock purchase warrants for cash of $4,225. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

The stock purchase warrants issued as part of the units (including over-allotment option) are exercisable for 3,272,500 shares of common stock at $6.60 per share beginning six months after the closing of the IPO for five years, expiring on May 8, 2020. Additionally, the Company issued additional warrants to its investment bankers to purchase 185,250 shares of common stock, on the same terms as the warrants issued with the units. The warrants were valued using the Black-Scholes option pricing model and are classified as equity.

In July 2015, the Company issued 1,136,364 shares of common stock to Merck GHI for cash consideration of $5.0 million (see Note 5).

Stock options

In 2002, the Company adopted the 2002 Stock Option and Restricted Stock Plan, or the 2002 Plan, pursuant to which the Company’s Board of Directors could grant either incentive stock options or non-qualified stock options, shares of restricted stock, shares of unrestricted common stock, and other share-based awards to officers and employees. In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan, or the 2008 Plan, pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan, or the 2015 Plan; the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2002 Plan or 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 1,355,000 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of September 30, 2015, 528,890 shares remain available for issuance under the 2015 Plan.

For the three months ended September 30, 2015 and 2014, the Company recorded $261,540 and $24,977, respectively, of stock compensation expense. For the nine months ended September 30, 2015 and 2014, the Company recorded $1,172,231 and $80,457, respectively, of stock compensation expense. The allocation of share-based compensation expense by operating expenses is as follows:

		Three months ended September 30,
		2015		2014
Research and development	$	59,688	$	1,528
General and administrative		156,236		22,460
Sales and marketing		45,616		989
	$	261,540	$	24,977

	Nine months ended September 30,
	2015		2014
Research and development	$	161,819	$	3,903
General and administrative		443,267		74,032
Sales and marketing		567,145		2,522
	$	1,172,231	$	80,457

During the nine months ended September 30, 2015, the Company granted stock options to acquire 1,660,387 shares of common stock at a weighted average exercise price of $2.87 per share. The 2015 awards had a weighted average grant date fair value per share of $3.16. The Company has total stock options to acquire 1,948,249 shares of common stock outstanding at September 30, 2015.

Restricted stock units

In March 2014, the Company awarded restricted stock units to acquire 130,640 shares of common stock to its Chief Executive Officer. The restricted stock units were compensation for his service as Chief Executive Officer, or CEO, from October 2013 through June 2014 and were subject to forfeiture if he did not continue to perform management services through October 24, 2014. The restricted stock units vested on October 24, 2014 and 130,640 shares of common stock were issued to the CEO.

Stock purchase warrants

The Company has total stock purchase warrants to acquire 3,716,355 and 33,594 shares of common stock outstanding at September 30, 2015 and December 31, 2014, respectively. In the first quarter of 2015, the Company issued 225,011 warrants in connection with the issuance of its 2015 convertible debt. In the second quarter of 2015 in connection with the Company’s IPO, the Company issued 3,457,750 stock purchase warrants to investors and to its investment bankers. As of September 30, 2015, the warrants are classified as equity.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Commitments and contingencies

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 10 - Commitments and contingencies

Operating leases

During the second quarter 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five-year renewal at the Company’s election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. The Company also leases a facility in Woburn, Massachusetts under an operating lease that expires in January 2016, and provides the Company with options to extend the lease beyond the current expiration date. Additionally, the Company leases office space in Denmark; this lease was extended in September 2015 and is currently on a month-to-month basis. Rent expense under the Company’s facility operating leases for the nine months ended September 30, 2015 and 2014 was $447,007 and $341,862 respectively.

Capital leases

The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2018. The leases require monthly principal and interest payments.

Registration and other shareholder rights

In connection with the Merger and the investment transactions (see Notes 4 and 5), the Company also entered into a Registration Rights Agreement with the AdvanDx stockholders receiving Merger Consideration and with Merck GHI, pursuant to which the investors were granted certain demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company's common stock. Merck GHI also received rights to participate on a pro-rata basis in future securities offerings by the Company.

On December 18, 2013, the Company entered into the Third Amended and Restated Investors' Rights Agreement (the "Investors' Rights Agreement") with investors acquiring promissory notes convertible into shares of the Company's Series A Preferred Stock. Following the IPO, the holders of 20% or more of the securities subject to the Investors' Rights Agreement have demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company's common stock.

License agreements, research collaborations and development agreements

9 Months Ended

Sep. 30, 2015

License Agreements Research Collaborations And Development Agreements [Abstract]

License agreements, research collaborations and development agreements

Note 11 - License agreements, research collaborations and development agreements

OpGen is a party to two license agreements to acquire certain patent rights and technologies. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized $7,484 and $23,810 of net royalty expense for the three months ended September 30, 2015 and 2014, respectively and ($13,769) and $73,142 of net royalty (income) expense for the nine months ended September 30, 2015 and 2014, respectively. In 2015, future minimum royalty fees are $20,000 under these agreements.

In September 2013, OpGen entered into a technology development agreement in which the Company would receive fixed milestone payments for meeting development milestones under the agreement. Since the milestones are substantive, the Company recognizes revenue in the periods in which the substantive milestones are achieved; the Company attained sixteen milestones during 2014. In addition, the Company received an upfront payment of $250,000, which is recognized on a straight-line basis over the term of the technology development agreement. The Company recognized total revenue of $208,340 and $1,133,340 during the nine months ended September 30, 2015 and 2014, respectively, and $27,780 and $172,220 during the three months ended September 30, 2015 and 2014, respectively, relating to this arrangement.

In July 2003, AdvanDx entered into a non-exclusive, non-sublicensable, worldwide license agreement with Life Technologies, Inc. (“Life Technologies”) to use certain patent rights that allow it to manufacture and sell certain products. The agreement was amended multiple times through 2009 to add additional features and modify certain terms and conditions. Life Technologies is entitled to certain royalties on product sales. The Company expensed royalties of $150,570 since the Merger.

Related party transactions

9 Months Ended

Sep. 30, 2015

Related party transactions

Note 12 - Related party transactions

In March 2014, the Company entered into a supply agreement with Fluidigm Corporation, or Fluidigm, under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company’s CEO and Chairman of the Board of Directors of the Company, is a director of Fluidigm.

On July 12, 2015, the Company entered into a letter agreement, or the Agreement, with Fluidigm to expand the companies' existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Agreement also expands the existing Supply Agreement between the Company and Fluidigm, and provides for expansion of the gene targets and organisms to be tested on the Company's existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE marked diagnostic tests for the purpose of detecting resistome genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term is extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Summary of significant accounting policies (Policies)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation and consolidation

Foreign Currency

Foreign Currency

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of estimates

Use of estimates

Fair value of financial instruments

Fair value of financial instruments

Cash and cash equivalents

Cash and cash equivalents

Accounts receivable

Accounts receivable

Inventories

Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	September 30,		December 31,
	2015		2014

Raw materials and supplies	$	697,414	$	40,749
Work-in process		222,031		135,625
Finished goods		236,043		193,368
Total	$	1,155,488	$	369,742

Product warranty

Product warranty

Impairment of long-lived assets

Impairment of property and equipment

Intangible assets and goodwill

Intangible assets and goodwill

Intangible assets were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill.

Definite-lived intangible assets

Goodwill

Redeemable convertible preferred stock

Redeemable convertible preferred stock

Revenue recognition

Revenue recognition

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

Revenue from sales of AdvanDx diagnostic products

Revenue from sales of AdvanDx diagnostic products typically is recognized when the product is delivered to the customer.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

Share-based compensation

Share-based compensation

Income taxes

Income taxes

Loss per share

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

Recent accounting pronouncements

Recent accounting pronouncements

Summary of significant accounting policies (Tables)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Schedule of inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	September 30,		December 31,
	2015		2014

Raw materials and supplies	$	697,414	$	40,749
Work-in process		222,031		135,625
Finished goods		236,043		193,368
Total	$	1,155,488	$	369,742

Business Combination (Tables)

9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Schedule of preliminary allocation of the purchase price

The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued	$	2,584,090

Fair value of tangible assets acquired:
Cash		1,367,211
Receivables		557,112
Inventory		1,073,855
Property and equipment		250,636
Other assets		359,587
Fair value of identifiable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		291,747

Fair value of liabilities assumed		3,329,058
	$	2,584,090

Schedule of unaudited pro forma financial information

Unaudited pro forma results	Nine months ended				Three months ended
	September 30,		September 30,		September 30,		September 30,
	2015		2014		2015		2014

Revenues	$	3,902,337	$	6,631,510	$	1,126,530	$	1,955,894
Net loss	$	(15,623,109)	$	(11,784,997)	$	(4,650,817)	$	(4,517,541)
Net loss per share	$	(2.29)	$	(11.72)	$	(0.38)	$	(4.49)

Fair value measurements (Tables)

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014:

	Fair value at
	September 30,
	2015		Level 1		Level 2		Level 3
Cash and cash equivalents	$	11,187,129	$	11,187,129	$	-	$	-

	Fair value at
	December 31,
	2014		Level 1		Level 2		Level 3
Cash and cash equivalents	$	749,517	$	748,048	$	1,469	$	-

Summary of change in fair value classified as Level 3 liabilities measured at fair value on a recurring basis

The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2015:

	Balance at								Balance at
	December		Established		Change in		Reclassified		September
Description	31, 2014		in 2015		Fair Value		to Equity		30, 2015

Derivative warrant liability	$	-	$	72,333	$	647,342	$	(719,675)	$	-

Stockholders' equity (deficit) (Tables)

9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Schedule of allocation of share-based compensation expense

The allocation of share-based compensation expense by operating expenses is as follows:

		Three months ended September 30,
		2015		2014
Research and development	$	59,688	$	1,528
General and administrative		156,236		22,460
Sales and marketing		45,616		989
	$	261,540	$	24,977

	Nine months ended September 30,
	2015		2014
Research and development	$	161,819	$	3,903
General and administrative		443,267		74,032
Sales and marketing		567,145		2,522
	$	1,172,231	$	80,457

Liquidity and management's plans (Details Textual) - USD ($)			3 Months Ended		6 Months Ended	9 Months Ended
	Jul. 14, 2015	May 08, 2015	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Conversion of Stock [Line Items]
Proceeds from Notes Payable						$ 1,741,667	$ 0
Stock And Warrants Issued During Period Shares Initial Public Offering		2,850,000
Stock And Warrants Issued During Period Shares Initial Public Offering Purchase Price Per Unit		$ 6.00
Proceeds From Issuance Of Units Under Initial Public Offering Gross		$ 17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		12,100,000
Debt Conversion, Original Debt, Amount		$ 2,100,000
Conversion of Stock, Shares Issued		7,374,852
Proceeds from Issuance of Common Stock						4,958,335	0
Debt Conversion, Converted Instrument, Amount						300,000	0
Merck Global Health Innovation Fund LLC \| AdvanDx Inc [Member]
Conversion of Stock [Line Items]
Proceeds From Issuance Of Shares And Debt	$ 6,000,000
Common Stock
Conversion of Stock [Line Items]
Stock And Warrants Issued During Period Shares Initial Public Offering		422,500
Proceeds From Issuance Of Units Under Initial Public Offering Gross		$ 17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		12,100,000
Common Stock \| Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Sale of Stock, Price Per Share	$ 4.40
Sale of Stock, Number of Shares Issued in Transaction	1,136,364
Proceeds from Issuance of Common Stock	$ 5,000,000
Initial public offering
Conversion of Stock [Line Items]
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Debt Conversion, Converted Instrument, Amount						2,100,000	$ 0
Convertible Notes Payable
Conversion of Stock [Line Items]
Proceeds from Convertible Debt						1,500,000
Short-term Demand Notes
Conversion of Stock [Line Items]
Proceeds from Notes Payable					$ 2,300,000	800,000
Repayments of Notes Payable			$ 200,000
Debt Conversion, Converted Instrument, Amount				$ 300,000
Promissory Note \| Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Debt Instrument, Face Amount	$ 1,000,000
Promissory Note \| Common Stock \| Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Proceeds From Issuance Of Common Stock And Notes Payable						$ 6,000,000

Summary of significant accounting policies (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventories
Raw materials and supplies	$ 697,414	$ 40,749
Work-in process	222,031	135,625
Finished goods	236,043	193,368
Total	$ 1,155,488	$ 369,742

Summary of significant accounting policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Jun. 30, 2015	May 08, 2015
Significant Accounting Policies [Line Items]
Allowance for Doubtful Accounts Receivable	$ 79,697		$ 79,697		$ 79,697
Inventory Valuation Reserves	$ 778,944		$ 778,944		867,816
Operating Loss Carryforwards					76,267,809
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,700,000	6,100,000	5,700,000	6,100,000
Cash, FDIC Insured Amount	$ 250,000		$ 250,000
Product Warranty Accrual	2,750		2,750		2,750
Goodwill	$ 291,747		$ 291,747		$ 0
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			7 years
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			7 years
Trademarks [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years
Common Stock [Member]
Significant Accounting Policies [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion						7,374,852	7,374,852
Series A Convertible Redeemable Preferred Stock
Significant Accounting Policies [Line Items]
Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required			70.00%
Temporary Equity, Shares Outstanding	0		0		3,999,864
Accounts Receivable \| Customer One
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			12.00%		79.00%
Accounts Receivable \| Customer Two
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage			11.00%		15.00%
Maximum
Significant Accounting Policies [Line Items]
Accounts Receivable Period Due			45 days
Minimum
Significant Accounting Policies [Line Items]
Accounts Receivable Period Due			30 days

Business Combination (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair value of identifiable intangible assets acquired:
Fair value of goodwill	$ 291,747	$ 0
AdvanDx [Member]
Business Acquisition [Line Items]
Total purchase price - fair value of common stock issued	2,584,090
Fair value of tangible assets acquired:
Cash	1,367,211
Receivables	557,112
Inventory	1,073,855
Property and equipment	250,636
Other assets	359,587
Fair value of identifiable intangible assets acquired:
Customer relationships	1,094,000
Developed technology	458,000
Trademarks and tradenames	461,000
Fair value of goodwill	291,747
Fair value of liabilities assumed	3,329,058
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Total	$ 2,584,090

Business Combination (Details 1) - USD ($)	3 Months Ended		9 Months Ended
Business Combination (Details 1) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition, Pro Forma Information
Revenues	$ 1,126,530	$ 1,955,894	$ 3,902,337	$ 6,631,510
Net loss	$ (4,650,817)	$ (4,517,541)	$ (15,623,109)	$ (11,784,997)
Net loss per share	$ (0.38)	$ (4.49)	$ (2.29)	$ (11.72)

Business Combination (Details Textual) - USD ($)		3 Months Ended		9 Months Ended
Business Combination (Details Textual) - USD ($)	Jul. 14, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Goodwill		$ 291,747		$ 291,747		$ 0
Payments of Merger Related Costs, Financing Activities				500,000
Revenues, Total		980,786	$ 834,824	1,828,133	$ 3,004,246
Net Income (Loss) Attributable to Parent		(4,670,582)	$ (1,608,833)	(12,624,339)	$ (4,265,887)
AdvanDx [Member]
Business Acquisition [Line Items]
Goodwill		$ 291,747		291,747
Revenues, Total				800,000
Net Income (Loss) Attributable to Parent				$ 800,000
AdvanDx [Member] \| Equity Issued in Business Combination [Member]
Business Acquisition [Line Items]
Stock Issued During Period Shares for Meger	681,818
Shareholders' Equity, Fair Value Disclosure	$ 2,600,000

Merck GHI Financing (Details Textual) - USD ($)		9 Months Ended
Merck GHI Financing (Details Textual) - USD ($)	Jul. 14, 2015	Sep. 30, 2015	Sep. 30, 2014
Common Stock and Note Purchase Agreement [Line Items]
Proceeds from Issuance of Common Stock		$ 4,958,335	$ 0
Merck GHI Financing Agreement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	1,136,364
Shares Issued, Price Per Share	$ 4.40
Proceeds from Issuance of Common Stock	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 1,000,000
Fees Related to Common Stock and Debt Transaction	50,000
Payments of Debt Issuance Costs	8,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 42,000

Fair value measurements (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair value measurements on recurring basis
Cash and cash equivalents	$ 11,187,129	$ 749,517
Level 1
Fair value measurements on recurring basis
Cash and cash equivalents	11,187,129	748,048
Level 2
Fair value measurements on recurring basis
Cash and cash equivalents	0	1,469
Level 3
Fair value measurements on recurring basis
Cash and cash equivalents	$ 0	$ 0

Fair value measurements (Details 1) - Warrant	9 Months Ended
Fair value measurements (Details 1) - Warrant	Sep. 30, 2015 USD ($)
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the begining of the period	$ 0
Established in 2015	72,333
Change in Fair Value	647,342
Reclassifed to Equity	(719,675)
Balance at the end of the period	$ 0

Series A redeemable convertible preferred stock (Details Textual) - USD ($)		1 Months Ended			9 Months Ended
	May 08, 2015	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2013	Sep. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount	$ 2,100,000
Conversion of Stock, Shares Issued	7,374,852
Series A Preferred Stock
Class of Stock [Line Items]
Temporary Equity, Shares Issued		594,904	1,405,096	1,999,864
Temporary Equity, Par or Stated Value Per Share				$ 1.00
Debt Conversion, Original Debt, Amount				$ 1,999,864
Proceeds from Issuance of Convertible Preferred Stock		$ 594,904	$ 1,405,096
Temporary Equity, Shares Outstanding						3,999,864
Temporary Equity Shares Outstanding Convertible Into Common Stock Number						3,999,864
Preferred Stock, Dividend Rate, Percentage					8.00%
Temporary Equity Liquidation And Redemption Preference Multiple Of Purchase Price					2
Conversion of Stock, Shares Issued					1
Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required					70.00%
Temporary Equity Redemption Number Of Installments					3
Debt Conversion, Converted Instrument, Shares Issued					7,374,852

Debt (Details Textual)		1 Months Ended		2 Months Ended	3 Months Ended				6 Months Ended	9 Months Ended
Debt (Details Textual)	May 08, 2015 USD ($)	Jul. 31, 2015 USD ($)	May 31, 2015 USD ($) shares	Mar. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($)	Mar. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)
Debt Instrument [Line Items]
Proceeds from Notes Payable										$ 1,741,667	$ 0
Debt Conversion, Converted Instrument, Amount										300,000	0
Fair Value Adjustment of Warrants	$ 700,000				$ 0			$ (4,400)		647,342	(4,400)
Interest Expense, Debt			$ 1,500,000								1,500,000
Amortization of Financing Costs										71,421
Common Stock Percent				8.00%			8.00%		8.00%
Common Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				225,011			225,011		225,011
IPO [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount										2,100,000	$ 0
Debt Conversion, Converted Instrument, Shares Issued \| shares			1,875,000
IPO [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued \| shares			350,000
2014 Convertible Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								8.00%			8.00%
Proceeds from Other Short-term Debt								$ 1,500,000
2015 Convertible Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%		0.00%	8.00%		8.00%
Proceeds from Other Short-term Debt		$ 1,000,000		$ 1,500,000		$ 150,000
Convertible Notes Payable					$ 1,001,250					1,001,250
2015 Convertible Notes \| Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price \| $ / shares				$ 1.00			$ 1.00		$ 1.00
2015 Convertible Notes \| Pre IPO
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio				1.25
2015 Convertible Notes \| Post IPO
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio				1.00
Short-term Demand Notes
Debt Instrument [Line Items]
Proceeds from Notes Payable									$ 2,300,000	$ 800,000
Debt Conversion, Converted Instrument, Amount							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%					8.00%

Stockholders' equity (deficit) (Details) - USD ($)	3 Months Ended		9 Months Ended
Stockholders' equity (deficit) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 261,540	$ 24,977	$ 1,172,231	$ 80,457
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	59,688	1,528	161,819	3,903
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	156,236	22,460	443,267	74,032
Sales and marketing activities
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 45,616	$ 989	$ 567,145	$ 2,522

Stockholders' equity (deficit) (Details Textual) - USD ($)			1 Months Ended			3 Months Ended			9 Months Ended
	Jul. 14, 2015	May 08, 2015	Jul. 31, 2015	Oct. 24, 2014	Mar. 31, 2014	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 261,540		$ 24,977	$ 1,172,231	$ 80,457
Debt Conversion, Converted Instrument, Amount									300,000	0
Stock Purchase Warrants Issued Upon Conversion Over Allotment Option		422,500
Proceeds from Issuance of Warrants		$ 4,225
Proceeds From Issuance Of Units Under Initial Public Offering Gross		17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Stock Issued During Period, Value, Acquisitions									$ 2,584,090	0
Merck Global Health Innovation Fund LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues			1,136,364
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,272,500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.60
Expiration Date of Warrants Issued		May 08, 2020
Demand Notes Payable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 2,100,000
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,355,000			1,355,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						528,890			528,890
Share-based Compensation Arrangement by Share-based Payment Award, Common stock Pecentage									4.00%
Stock Purchase Warrants Issued							3,457,750
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 261,540		$ 24,977	$ 1,172,231	$ 80,457
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									1,660,387
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 2.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value									$ 3.16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						1,948,249			1,948,249
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					130,640
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				130,640
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Outstanding						3,716,355			3,716,355			33,594
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock and Warrants Issued in Conjunction with Initial Public Offering		2,850,000
Offering Price Per Unit		$ 6.00
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 2,900,000
Convertible Preferred Stock, Shares Issued upon Conversion		7,374,852					7,374,852
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											225,011
Proceeds From Issuance Of Units Under Initial Public Offering Gross		$ 17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Common Stock [Member] \| Merck Global Health Innovation Fund LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Acquisitions	$ 5,000,000
Common Stock [Member] \| Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		185,250

Commitments and contingencies (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net	$ 447,007	$ 341,862

License agreements, research collaborations and development agreements (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
License Agreements Research Collaborations And Development Agreements [Line Items]
Future Minimum Royalty Payments Due		$ 20,000			$ 20,000
License Upfront Payment Received	$ 250,000
Royalty (Income) Expense		7,484	$ 23,810		(13,769)	$ 73,142
Licenses Revenue		27,780		$ 172,220	$ 208,340	$ 1,133,340
Life Technologies [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Royalty (Income) Expense		$ 150,570